Our results indicate that enhancing tumor immunogenicity and increasing the population of deficient PD-1+ CD8 TILs are essential for improving the efficacy of anti-PD-1 therapy in a T-lymphopenic environment. This evidence concerns the gene PDCD1 and neoplasm.